Kras G12c Mutated Non Small Cell Lung Cancer Therapeutics
1. Krazati patent expiration
Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10689377 | BRISTOL | KRas G12C inhibitors |
May, 2037
(11 years from now) | |
| US12281113 | BRISTOL | Crystalline forms of a KRas G12C inhibitor |
Sep, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336995 | BRISTOL | NA |
Feb, 2041
(15 years from now) | |
| US12383503 | BRISTOL | NA |
Aug, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
| Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Dosage: TABLET
More Information on Dosage
KRAZATI family patents
2. Lumakras patent expiration
Treatment: In combination with panitumumab for the treatment of adult patients with kras g12c-mutated metastatic colorectal cancer (mcrc), as determined by an fda-approved test, who have received prior chemother...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12398133 | AMGEN INC | NA |
May, 2040
(14 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(14 years from now) | |
| US11827635 | AMGEN INC | Solid state forms |
May, 2040
(14 years from now) | |
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12280056 | AMGEN INC | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
Nov, 2039
(13 years from now) | |
| US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Sep, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| New Indication(I-962) | Jan 16, 2028 |
| ODE*(ODE*) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-352) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-507) | Jan 16, 2032 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Dosage: TABLET
More Information on Dosage
LUMAKRAS family patents